Retatrutide with MOTS-c
Commonly runA triple incretin agonist next to a mitochondrial peptide, on the argument that losing weight fast is easier than losing it well. The second half has never finished a human trial.
- Retatrutide
- MOTS-c
16 weeks
Reference
Stacks
A stack is several compounds run together, each on its own dose and schedule. Combinations are discussed constantly and studied almost never, so every page here is explicit about where the evidence for the combination stops.
Check a combination against our interaction dataBuild and share your own
Documented stacks
Written and cited by us, with full schedules
CJC-1295, ipamorelin and MK-677
Commonly runThe two-receptor growth hormone pairing with an oral secretagogue stacked on top. Three compounds, two of them acting on the same receptor.
- CJC-1295
- Ipamorelin
- MK-677
12 weeks
BPC-157, TB-500 and GHK-Cu
Commonly runThe repair pairing with a copper peptide added for connective tissue. Three preclinical compounds, and the copper is the one with an actual ceiling.
- BPC-157
- TB-500
- GHK-Cu
10 weeks
A GLP-1 with 5-Amino-1MQ
Commonly runAn incretin agonist doing the established work, with an oral NNMT inhibitor added on a mechanism that has never been tested in a person. One half of this has phase 3 trials; the other half has mice.
- Retatrutide
- 5-Amino-1MQ
16 weeks
NAD+ with Epitalon
Commonly runThe commonly run longevity pairing, and the one where the two compounds' problems are different: NAD+ has a delivery problem, Epitalon has a replication problem.
- NAD+
- Epitalon
10 weeks
BPC-157 and TB-500
Commonly runThe most commonly run repair pairing. Two compounds on different schedules, on the reasoning that one builds blood supply and the other moves cells into the gap.
- BPC-157
- TB-500
8 weeks
CJC-1295 and Ipamorelin
Commonly runThe standard growth hormone pairing. Two compounds on two different receptors, which is the one combination in this category with a real mechanistic argument.
- CJC-1295
- Ipamorelin
12 weeks
Tesamorelin and Ipamorelin
Commonly runThe same two-receptor logic as CJC-1295 and ipamorelin, with the one GHRH analogue that has an approved indication behind it.
- Tesamorelin
- Ipamorelin
12 weeks
A GLP-1 agonist with an amylin analogue. The one combination in this category being developed as an actual drug, and the reason it earns a proper write-up.
- Semaglutide
- Cagrilintide
20 weeks
BPC-157 and GHK-Cu
Commonly runThe two components of GLOW without the TB-500, run separately so each can be dosed on its own schedule and route.
- GHK-Cu
- BPC-157
12 weeks
Shared by people running them
Published by their authors, newest first
Individual people’s plans, published by them. We did not write them, check them, or verify anyone followed them — one person doing something is not evidence that it works.
Nobody has published one yet. Group your own protocols into a stack — it stays private until you choose otherwise.
Next
Where to go from a stack
- Check your own combinationPut in what you are running and see what our profiles record about every pair, including the pairs nothing is recorded about.
- Build one in the trackerGroup protocols into a plan, write notes as it runs, and publish it only if you decide to.
- Read the compounds firstEvery compound in every stack above has a profile stating what the evidence actually is.